CurrentCardio
Get Weekly

Heart failure & cardiomyopathies

Early Discharge Strategy Including Subcutaneous Furosemide in Hospitalized Heart Failure

J Am Coll CardiolPublished

Primary result · DAOHResultDifference 4.0 days 95% CI 2.1–5.8
  • multicenter, open-label, randomized, active-controlled trial
  • United Kingdom
+1 more
  • United Kingdom
Read the original article ↗

Authors' conclusion

An early discharge strategy using a subcutaneous furosemide minipump increased DAOH compared with usual care. (Use of a Novel SUBCUTaneous Preparation of Furosemide to Facilitate Early Supported Discharge of Patients With Heart Failure [SUBCUT-HF II]; NCT05419115).

Study context

Population
Patients hospitalized for heart failure requiring ongoing parenteral diureticsrandomly assigned
Participants
172 patients
Comparison
early discharge strategy or usual care
  • early dischargen = 92
  • usual caren = 80reference
Primary endpoint
DAOH
Follow-up
30 days after randomization

Primary result

DAOH

Difference

4.0 days

95% CI 2.1–5.8

P < 0.001

early discharge vs usual care
difference 4.0 days (95% CI 2.1–5.8); P < 0.001

As reported in the abstract

Further findings

Outcomedifference (days) (95% CI)P value
DAOH · 60 days · more DAOH with early discharge (benefit in DAOH sustained)4.2 (0.9–7.6)
Outcomeearly dischargeusual careOR (95% CI)P value
Heart failure readmissions14%6%2.45 (0.81–7.43)
Outcomemean difference (days) (95% CI)P value
Index hospitalization length · shorter with early discharge5.5 (7.4–3.6)P < 0.001

Safety

Serious adverse events

Device-related problems (minipump placements)

Device-related problems with minipump placements
3%
None were serious

Original publication

Early Discharge Strategy Including Subcutaneous Furosemide in Hospitalized Heart Failure. J Am Coll Cardiol. Published 13 October 2026. doi:10.1016/j.jacc.2026.07.047
Read the original article ↗PubMedCite NBIB · RIS · BibTeX

Summarised from the published abstract; every number is checked against it